A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)
Completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator
Sufficient tumor tissue for planned analysis
ECOG performance status of 0 or 1
Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in all other participating countries patients must be 18 years of age to consent
You may not be if
Pure sarcomas or borderline tumors or mucinous tumors
Active second malignancy
Known central nervous system brain metastases
Any prior treatment for ovarian cancer, other than the first-line platinum regimen
Evidence of interstitial lung disease or active pneumonitis
Active, known or suspected autoimmune disease
Condition requiring active systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications
Clareo Health | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
